Results 21 to 30 of about 24,991 (171)

A comprehensive review of prognostic scoring systems to predict survival after transjugular intrahepatic portosystemic shunt placement

open access: yesPortal Hypertension &Cirrhosis, Volume 1, Issue 2, Page 133-144, September 2022., 2022
Prognostic tools for survival prediction and risk stratification after transjugular intrahepatic portosystemic shunt placement. Abstract Patient prognosis after transjugular intrahepatic portosystemic shunt (TIPS) placement is relatively poor and highly heterogeneous; therefore, a prognostic scoring system is essential for survival prediction and risk ...
Chongtu Yang, Bin Xiong
wiley   +1 more source

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment

open access: yesThe Journal of Clinical Pharmacology, Volume 62, Issue 6, Page 812-822, June 2022., 2022
Abstract Acalabrutinib received approval for the treatment of adult patients with mantle cell lymphoma who received at least 1 prior therapy and adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This study investigated the impact of hepatic impairment (HI) on acalabrutinib pharmacokinetics (PK) and safety at a single 50‐mg
Yan Xu   +13 more
wiley   +1 more source

Late Bleeding Episodes Following Intestinal Transplantation

open access: yesJPGN Reports, Volume 3, Issue 2, May 2022., 2022
Ectopic varices have been reported in 5% of children presenting with variceal bleeding and are defined as portosystemic venous collaterals occurring anywhere in the abdomen except in the cardioesophageal region. The liver‐intestinal transplant or isolated liver‐intestinal transplant patient presenting several years post‐transplant with ectopic variceal
Harveen Singh   +6 more
wiley   +1 more source

Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single‐Dose, Matched Case‐Control Study

open access: yesClinical Pharmacology in Drug Development, Volume 10, Issue 7, Page 707-717, July 2021., 2021
Abstract This phase I open‐label trial (NCT03627754) assessed glasdegib pharmacokinetics and safety in otherwise healthy participants with moderate (Child‐Pugh B) or severe (Child‐Pugh C) hepatic impairment. Participants with hepatic impairment and age/weight‐matched controls with normal hepatic function received a single oral 100‐mg glasdegib dose ...
Joanna C. Masters   +4 more
wiley   +1 more source

Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling

open access: yesESC Heart Failure, Volume 8, Issue 1, Page 129-138, February 2021., 2021
Abstract Aims In patients at high risk of heart failure following myocardial infarction (MI) as a result of residual left ventricular systolic dysfunction (LVSD), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan may result in a greater attenuation of adverse left ventricular (LV) remodelling than renin angiotensin aldosterone system ...
Kieran F. Docherty   +11 more
wiley   +1 more source

Malignant Priapism as a Result of Metastatic Thyroid Cancer: A Hard Reality

open access: yesCase Reports in Urology, Volume 2021, Issue 1, 2021., 2021
Metastasis to the penis is an extremely rare entity. Malignant priapism is defined as a persistent, nonsexual erection that is refractory to pharmacologic treatment, corporal aspiration, and surgical shunts. Furthermore, it is typically a hallmark of an advanced cancer that has metastasized, most commonly from regional organs like the prostate or ...
Ethan Vargo   +5 more
wiley   +1 more source

Development of Ectopic Livers by Hepatocyte Transplantation Into Swine Lymph Nodes

open access: yesLiver Transplantation, Volume 26, Issue 12, Page 1629-1643, December 2020., 2020
Orthotopic liver transplantation continues to be the only effective therapy for patients with end‐stage liver disease. Unfortunately, many of these patients are not considered transplant candidates, lacking effective therapeutic options that would address both the irreversible progression of their hepatic failure and the control of their portal ...
Paulo Fontes   +4 more
wiley   +1 more source

Ante-situm resection: a novel approach to avoid extracorporeal circulation using a transient portacaval shunt.

open access: yesHPB, 2015
Hepatic tumours located at the hepatocaval confluence or compromising the inferior vena cava (IVC) are not often resectable using conventional techniques. To overcome this problem, different surgical procedures have been described.
E. de Santibañes   +6 more
semanticscholar   +1 more source

L‐Ornithine L‐Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle

open access: yesCanadian Journal of Gastroenterology and Hepatology, Volume 2019, Issue 1, 2019., 2019
Sarcopenia is a common complication of cirrhosis with a negative impact on posttransplant outcome, health‐related quality of life (HRQOL), and patient survival. Studies in experimental animals and in patients demonstrate that ammonia is directly implicated in the pathogenesis of sarcopenia in cirrhosis via mechanisms involving increased expression of ...
Roger F. Butterworth, Quirino Lai
wiley   +1 more source

Direct Costs of Care in a Randomized Controlled Trial of Endoscopic Sclerotherapy versus Emergency Portacaval Shunt for Bleeding Esophageal Varices in Cirrhosis—Part 4

open access: yesJournal of Gastrointestinal Surgery, 2010
BackgroundEmergency treatment of bleeding esophageal varices (BEV) in cirrhotic patients is of prime importance because of the high mortality rate surrounding the episode of acute bleeding. Nevertheless, there is a paucity of randomized controlled trials
M. Orloff   +7 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy